July 01, 2025

Stem Cell Therapy Shows T1D Reversal Potential

A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

CGM Boosts Wound Healing, Lowers A1c: Study

Short-term CGM use improved A1c, wound healing, and reduced ED visits in diabetic foot patients, per data from ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Lower Sleep HRV May Predict Parkinson Disease Onset

A study of patients with REM sleep behavior disorder found that lower heart rate variability during sleep may indicate early signs of neurodegenerative disease, particularly Parkinson’s.

Conexiant

June 25, 2025

Blood Marker May Predict Faster Brain Decline

A new study found that higher triglyceride-glucose index levels, a marker of insulin resistance, were linked to faster cognitive decline in early Alzheimer's, suggesting potential for improved risk assessment in clinical settings.

Conexiant

June 25, 2025

Nighttime Heart Rhythms Predict Brain Disorders

A large Swiss study found that nighttime heart rate patterns may predict future risk for brain and psychiatric disorders, while traditional sleep structure measures were less informative.

Conexiant

June 25, 2025

Combo Obesity Therapy Preserves Muscle, Reduces Fat

A new combination therapy of semaglutide and bimagrumab helped patients lose more fat while preserving muscle mass, while a novel biosensor may help track muscle loss during obesity treatment.

Conexiant

June 24, 2025

Liraglutide Linked to Fewer Migraine Days

A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.

Conexiant